What are the current guidelines for administering Iloprost infusions in patients with severe Raynaud's Phenomenon?

Iloprost infusions are a recommended treatment for severe Raynaud's Phenomenon, especially after failure of oral therapies. They are administered at doses of 0.5-2.0 ng/kg/min over several days, requiring monitoring for vasodilatory side effects.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-12
DOI
https://doi.org/10.5281/zenodo.24155818
Primary Topic
Systemic Sclerosis and Related Diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

What are the current guidelines for administering Iloprost infusions in patients with severe Raynaud's Phenomenon?

Tripdatabase
Zenodo (CERN European Organization for Nuclear Research)
Systemic Sclerosis and Related Diseases
article

What are the current guidelines for administering Iloprost infusions in patients with severe Raynaud's Phenomenon?

Tripdatabase
article en

Abstract

Iloprost infusions are a recommended treatment for severe Raynaud's Phenomenon, especially after failure of oral therapies. They are administered at doses of 0.5-2.0 ng/kg/min over several days, requiring monitoring for vasodilatory side effects.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Systemic Sclerosis and Related Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon